.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Modern oncology continues to seek precision tools that minimize collateral damage to healthy tissues. Researchers have recently identified star-shaped fluorenyl-porphyrins as potent agents for two-photon photodynamic therapy. These hydrophobic compounds usually face challenges in aqueous biological environments. However, a new study demonstrates that encapsulating these photosensitizers within poly(benzyl malate) nanoparticles significantly improves their biocompatibility. Consequently, these formulations allow for effective treatment delivery in biological media without losing essential optical properties.
The research team systematically investigated how structural modifications to the porphyrin \"arms\" impact therapeutic performance. Specifically, they compared units linked by triple or double bonds to optimize light absorption. Notably, formulations with a high photosensitizer loading of 25 wt % showed promising activity. This strategy offers an accessible and cost-effective approach for biocompatibilization. Furthermore, the confinement of porphyrins within the nanoparticles did not diminish their luminescence. Therefore, these nanosystems serve as excellent candidates for bioimaging, fulfilling the requirements for theranostic applications.
Advancements in nanoparticle delivery systems are transforming the landscape of localized therapies. Because these systems use two-photon excitation, they offer deeper tissue penetration than traditional methods. This capability is particularly beneficial for treating deep-seated tumors. Additionally, the ability to track the photosensitizer via fluorescence allows clinicians to monitor drug distribution in real-time. In addition to oncology, these findings may impact dermatology and other specialties requiring targeted light-activated treatments.
Two-photon excitation uses longer wavelengths of light, which penetrate deeper into human tissues compared to single-photon methods. This allows for the treatment of deeper lesions while providing high spatial precision, reducing damage to surrounding healthy cells.
Fluorenyl-porphyrins are hydrophobic, meaning they do not dissolve well in water or biological fluids. Nanoparticles based on poly(benzyl malate) encapsulate these molecules, making them stable and biocompatible for clinical use in the human body.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or substitute for professional consultation. Refer to the latest local and national guidelines for clinical practice.
References
Gorbunova V et al. Biocompatible Nanoparticles Encapsulation of Fluorenyl-Porphyrins: Impact of Arm Structural Modifications on Two-Photon Phototherapeutic Performance. Biomacromolecules. 2026 Mar 25. doi: 10.1021/acs.biomac.5c02154. PMID: 41878882.
Li X et al. Nanomedicines for photodynamic therapy: A review. Journal of Controlled Release. 2020;328:641-678. doi:10.1016/j.jconrel.2020.09.020.
Abrahamse H, Hamblin MR. New photosensitizers for photodynamic therapy. Biochem J. 2016;473(4):347-364. doi:10.1042/BJ20150942.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Researchers enhance two-photon photodynamic therapy using nanoparticle-encapsulated fluorenyl-porphyrins for improved biocompatibility and theranostic perfo...
5 months ago
A new study reveals that lipid-related metabolic dysregulation, marked by elevated TG/HDL-C ratio and glymphatic changes, independently impacts survival in idiopathic normal pressure hydrocephalus.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
A meta-analysis of 13 propensity score-matched studies shows ViV-TAVR delivers lower early mortality and reduced bleeding compared to redo-SAVR for degenerated bioprosthetic aortic valves, though long-term hemodynamics warrant careful anatomical and patient-centered evaluation.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
